周一，Leerink Partners将Structure Therapeutics（NASDAQ:GPCR）的目标股价从此前的93美元下调至60美元，同时维持对该股票的"优于大市"评级。该公司股票目前交易价格为23.75美元，分析师目标价区间为50美元至118美元。根据InvestingPro数据显示，尽管该股票过去一年下跌约42%，但在过去一周仍录得近13%的涨幅。此次调整是在分析师David ...

M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

在动荡的市场环境下，Structure Therapeutics ADR（股票代码：GPCR）股价触及52周新低，达到$20.11，仅在过去一周就下跌了11.6%。根据 InvestingPro ...

Before Heptares was founded, the only resolved X-ray crystallography structure of a GPCR was rhodopsin. Other proteins, such as kinases, crystalize more readily, allowing chemists to employ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Outperform recommendation. Analyst Price ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and ...